Aihara T et al. Phase II study of
concurrent administration of doxorubicin and docetaxel
as first-line chemotherapy for metastatic breast cancer. Oncology
2003;64(2):124-30. Abstract.
Aihara T et al. Phase II study of weekly docetaxel
in patients with metastatic breast cancer. Ann
Oncol 2002;13(2):286-92. Abstract.
Alba E et al. Sequential doxorubicin and docetaxel
as first-line treatment in metastatic breast cancer: A
GEICAM-9801 phase II study. Breast Cancer Res
Treat 2003;77(1):1-8. Abstract.
Baltali E et al. Paclitaxel and doxorubicin combination
in the first-line treatment of metastatic breast cancer. Tumori
2002;88(3):200-3. Abstract.
Biganzoli L et al. Doxorubicin and paclitaxel versus
doxorubicin and cyclophosphamide as first-line chemotherapy
in metastatic breast cancer: The European Organization
for Research and Treatment of Cancer 10961 Multicenter
Phase III Trial. J Clin Oncol 2002;20(14):3114-21.
Abstract.
Gennari A et al. Weekly docetaxel/paclitaxel in
pretreated metastatic breast cancer. Clin Breast
Cancer 2002;3(5):346-52. Abstract.
Gori S et al. Weekly paclitaxel in metastatic breast
cancer patients: A phase II study. Tumori 2002;88(6):470-3.
Abstract.
Loesch D et al. Phase II multicenter trial of a
weekly paclitaxel and carboplatin regimen in patients with
advanced breast cancer. J Clin Oncol 2002;20(18):3857-64.
Abstract.
Mavroudis D et al. Salvage treatment of metastatic
breast cancer with docetaxel and carboplatin. A multicenter
phase II trial. Oncology 2003;64(3):207-12. Abstract.
Nabholtz JM et al. Docetaxel and doxorubicin compared
with doxorubicin and cyclophosphamide as first-line chemotherapy
for metastatic breast cancer: Results of a randomized,
multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75.
Abstract.
O'Shaughnessy J et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated
patients with advanced breast cancer: Phase III trial results. J
Clin Oncol 2002;20(12):2812-23. Abstract.
Perez EA et al. A randomized phase II study of
sequential docetaxel and doxorubicin/cyclophosphamide in
patients with metastatic breast cancer. Ann Oncol
2002;13(8):1225-35. Abstract.
Sledge GW et al. Phase III trial of doxorubicin,
paclitaxel, and the combination of doxorubicin and paclitaxel
as front-line chemotherapy for metastatic breast cancer:
An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92.
Abstract.
Smith RE et al. Phase II trial of doxorubicin/docetaxel/cyclophosphamide
for locally advanced and metastatic breast cancer: Results
from NSABP trial BP-58. Clin Breast Cancer. 2002;3(5):333-40.
Abstract.
Talbot DC et al. Randomised, phase II trial comparing
oral capecitabine (Xeloda) with paclitaxel in patients
with metastatic/advanced breast cancer pretreated with
anthracyclines. Br J Cancer 2002;86(9):1367-72.
Abstract.
Venturini M et al. Capecitabine in combination
with docetaxel and epirubicin in patients with previously
untreated, advanced breast carcinoma. Cancer 2003;97(5):1174-80.
Abstract.
|
